BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3731 related articles for article (PubMed ID: 23185849)

  • 1. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localised prostate cancer - current treatment options.
    Duchesne G
    Aust Fam Physician; 2011 Oct; 40(10):768-71. PubMed ID: 22003477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
    Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer?
    Merrick GS; Butler WM; Lief JH; Dorsey AT
    Tech Urol; 2001 Mar; 7(1):12-9. PubMed ID: 11272667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL; Thakral H; Wilson L; Schellhammer P
    J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional treatments of localized prostate cancer.
    Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
    Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?
    Radomski L; Gani J; Trottier G; Finelli A
    Can J Urol; 2012 Jun; 19(3):6287-92. PubMed ID: 22704315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
    J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.
    Chou R; Croswell JM; Dana T; Bougatsos C; Blazina I; Fu R; Gleitsmann K; Koenig HC; Lam C; Maltz A; Rugge JB; Lin K
    Ann Intern Med; 2011 Dec; 155(11):762-71. PubMed ID: 21984740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary grading for prostate cancer: implications for patient care.
    Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
    Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 187.